Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8626 to 8640 of 8994 results

  1. Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]

    In development Reference number: GID-TA10826 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    Discontinued Reference number: GID-TA11228

    Technology appraisal guidance
    Discontinued

  3. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Discontinued Reference number: GID-TA11343

    Technology appraisal guidance
    Discontinued

  4. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

    Discontinued Reference number: GID-TA11165

    Technology appraisal guidance
    Discontinued

  5. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    Discontinued Reference number: GID-TA11089

    Technology appraisal guidance
    Discontinued

  6. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    Discontinued Reference number: GID-TA11166

    Technology appraisal guidance
    Discontinued

  7. Colon cancer (adjuvant) - irinotecan [ID379]

    Discontinued Reference number: GID-TAG380

    Technology appraisal guidance
    Discontinued

  8. Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]

    In development Reference number: GID-TA11884 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]

    In development Reference number: GID-TA11654 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]

    In development Reference number: GID-TA11690 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine (TA53)

    This guidance has been replaced by NICE guideline NG17.

    Withdrawn guidance

  12. Farco-fill Protect for indwelling urinary catheterisation (MIB121)

    July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.

    Withdrawn advice

  13. Improving outcomes in urological cancers (CSG2)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

    Retired guideline

  14. Improving supportive and palliative care for adults with cancer (CSG4)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

    Retired guideline

  15. Improving outcomes in breast cancer (CSG1)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

    Retired guideline